Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TL;DR
Enveda raised $311 million in a Series E round led by Catalio Capital Management with participation from Iconiq, valuing the AI biotech at $2 billion, double its valuation a year ago. The company uses AI to discover medicines derived from plants and microbes instead of designing molecules purely in the lab. Several of its drug candidates are already in human trials, including one for severe skin conditions and one meant to preserve weight loss after patients stop taking GLP-1 drugs.
Nauti's Take
The funding is a promising signal for AI drug discovery, because Enveda already has candidates in human trials rather than only platform claims. The challenge is that clinical trials remain the real filter, and a doubled valuation assumes results that are still years away.
Investors and biotech watchers should track trial readouts; patients hoping for a GLP-1 follow-up drug should expect a long road before approval.
Sources